Physician profile
Mark K Smith
NPI 1154328433
$8,786.90
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,809 · 2020: $1,910 · 2021: $2,443 · 2022: $1,625.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,429.78 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $1,290.35 | 2019-2022 | |
| Amgen INC. | $942.31 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $673.84 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $659.83 | 2019-2022 | |
| Abbvie INC. | $489.20 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $466.10 | 2019-2022 | |
| Lilly USA, LLC | $414.27 | 2019-2022 | |
| Glaxosmithkline, LLC. | $402.84 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $391.22 | 2019-2020 | |
| Amarin Pharma, INC. | $214.78 | 2019-2022 | |
| Eisai INC. | $145.84 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $145.37 | 2022 | |
| Astellas Pharma US INC | $143.32 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $135.29 | 2020-2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $108.92 | 2021 | |
| Esperion Therapeutics, INC. | $98.96 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $91.96 | 2019-2021 | |
| Abbott Laboratories | $86.44 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.94 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.41 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $48.59 | 2021 | |
| Genentech USA, INC. | $37.96 | 2020-2021 | |
| Althera Pharmaceuticals LLC | $33.70 | 2021-2022 | |
| Nevro Corp. | $26.15 | 2022 | |
| Pfizer INC. | $25.53 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $22.45 | 2019 | |
| Mannkind Corporation | $15.78 | 2022 | |
| Medtronic, INC. | $15.32 | 2022 | |
| Antares Pharma, INC. | $15.04 | 2021 | |
| Nestle Healthcare Nutrition INC. | $15.02 | 2022 | |
| Gilead Sciences, INC. | $14.93 | 2020 | |
| Clarus Therapeutics INC. | $13.50 | 2021 | |
| Ironshore Pharmaceuticals INC. | $13.03 | 2019 | |
| Kaleo, INC. | $12.99 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.48 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $11.66 | 2019 | |
| Allergan, INC. | $11.00 | 2020 | |
| Janssen Biotech, INC. | $3.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.